1-7 of 7
Andres Forero, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 581.
https://doi.org/10.1182/blood.V130.Suppl_1.581.581
Published: 2017
Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1552.
https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552
Published: 2017
Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Noopur Raje, MD, Edward Anthony Faber, Jr., DO, MS, Paul G. Richardson, MD, Gary J. Schiller, MD, Raymond J. Hohl, MD, PhD, Adam D. Cohen, MD, Andres Forero, MD, Susan P. Carpenter, PhD, Damien Cronier, PhD, Christopher Kaiser, PhD, James E. Wooldridge, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2012) 120 (21): 447.
https://doi.org/10.1182/blood.V120.21.447.447
Published: 2012
Journal Articles

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Andres Forero, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J Kipps, MD, PhD, Fritz Offner, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, Jaime PeĢrez de Oteyza, Jose Francisco Tomas, Antonio Cuneo, MD, Weiya Zhang, Trishna Goswami, MD, Ramy Ibrahim, MD, Zhenling Yao, Ronald Herbst, PhD, Bruce D. Cheson, MD
Journal: Blood
Blood (2012) 120 (21): 3677.
https://doi.org/10.1182/blood.V120.21.3677.3677
Published: 2012
Journal Articles

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Nathan H. Fowler, MD, Stephen P. Kahanic, MD, Andres Forero, MD, Mihaela C. Munteanu, MS, Glen L. Davis, MS, Peter Brown, DPhil, Eric Van Den Neste, MD, Fritz C. Offner, MD, PhD, Dominique Bron, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2011) 118 (21): 778.
https://doi.org/10.1182/blood.V118.21.778.778
Published: 2011
Journal Articles

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Jennifer Wayne, MS, Kristen N. Ganjoo, MD, Andres Forero, MD, Brad Pohlman, MD, Sven de Vos, MD, PhD, Susan P. Carpenter, PhD, James E Wooldridge, MD, Shashidhara Marulappa, DVM, MVSc, MBA, Vinay Jain, MBBS, MD, FACP
Journal: Blood
Blood (2011) 118 (21): 4977.
https://doi.org/10.1182/blood.V118.21.4977.4977
Published: 2011
Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD
Journal: Blood
Blood (2011) 118 (21): 1648.
https://doi.org/10.1182/blood.V118.21.1648.1648
Published: 2011